The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas.
Department of Cell Biology and Physiology, UNC School of Medicine, Chapel Hill, NC.|Program in Molecular Biology and Biotechnology, UNC School of Medicine, Chapel Hill, NC.|Lineberger Comprehensive Cancer Center, UNC School of Medicine, Chapel Hill, NC.
Lola M
LM
Reid
Lineberger Comprehensive Cancer Center, UNC School of Medicine, Chapel Hill, NC.|Department of Genetics, UNC School of Medicine, Chapel Hill, NC.
Praveen
P
Sethupathy
D014408:Biomarkers, Tumor / Q000235:genetics*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000235:genetics*; D054751:Cyclic AMP-Dependent Protein Kinase Catalytic Subunits / Q000187:drug effects / Q000235:genetics*; D050956:HSP40 Heat-Shock Proteins / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000187:drug effects / Q000235:genetics*
D014408:Biomarkers, Tumor; C494647:DNAJB1 protein, human; D050956:HSP40 Heat-Shock Proteins; D015514:Oncogene Proteins, Fusion; D054751:Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; C517757:PRKACA protein, human